相似文献
1
Location, location, location: macrophage positioning within tumors determines pro- or antitumor activity.
Cancer Cell. 2013 Dec 9;24(6):687-9. doi: 10.1016/j.ccr.2013.11.014.
2
Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity.
Cancer Cell. 2013 Dec 9;24(6):695-709. doi: 10.1016/j.ccr.2013.11.007.
3
Neuropilin-1 promotes human glioma progression through potentiating the activity of the HGF/SF autocrine pathway.
Oncogene. 2007 Aug 16;26(38):5577-86. doi: 10.1038/sj.onc.1210348. Epub 2007 Mar 19.
4
Double attack on tumors by targeting with guidance molecules.
Arterioscler Thromb Vasc Biol. 2011 Apr;31(4):721-2. doi: 10.1161/ATVBAHA.110.222240.
5
The influence of neuropilin-1 silencing on semaphorin 3A and 3C activity in B16(F10) murine melanoma cells.
Neoplasma. 2012;59(1):43-51. doi: 10.4149/neo_2012_006.
6
Autocrine semaphorin 3A signaling promotes glioblastoma dispersal.
Oncogene. 2009 Oct 8;28(40):3537-50. doi: 10.1038/onc.2009.204. Epub 2009 Aug 17.
7
Expression and function of semaphorin 3A and its receptors in human monocyte-derived macrophages.
Hum Immunol. 2009 Apr;70(4):211-7. doi: 10.1016/j.humimm.2009.01.026. Epub 2009 Feb 7.
8
Neuropilin-1 identifies a subset of bone marrow Gr1- monocytes that can induce tumor vessel normalization and inhibit tumor growth.
Cancer Res. 2012 Dec 15;72(24):6371-81. doi: 10.1158/0008-5472.CAN-12-0762. Epub 2012 Dec 7.
9
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth.
Cancer Cell. 2007 Jan;11(1):53-67. doi: 10.1016/j.ccr.2006.10.018.
10
Interplay of neuropilin-1 and semaphorin 3A after partial hepatectomy in rats.
World J Gastroenterol. 2012 Sep 28;18(36):5034-41. doi: 10.3748/wjg.v18.i36.5034.
引用本文的文献
1
Blocking ITGA5 potentiates the efficacy of anti-PD-1 therapy on glioblastoma by remodeling tumor-associated macrophages.
Cancer Commun (Lond). 2025 Mar 14. doi: 10.1002/cac2.70016.
2
Targeting tumor-associated macrophages with nanocarrier-based treatment for breast cancer: A step toward developing innovative anti-cancer therapeutics.
Heliyon. 2024 Aug 30;10(18):e37217. doi: 10.1016/j.heliyon.2024.e37217. eCollection 2024 Sep 30.
3
Dual CSF1R inhibition and CD40 activation demonstrates anti-tumor activity in a 3D macrophage- HER2 breast cancer spheroid model.
Front Bioeng Biotechnol. 2023 Jun 6;11:1159819. doi: 10.3389/fbioe.2023.1159819. eCollection 2023.
4
SET/PP2A signaling regulates macrophage positioning in hypoxic tumor regions by amplifying chemotactic responses.
Exp Mol Med. 2022 Oct;54(10):1741-1755. doi: 10.1038/s12276-022-00867-0. Epub 2022 Oct 12.
5
Osteoclast-like stromal giant cells in breast cancer likely belong to the spectrum of immunosuppressive tumor-associated macrophages.
Front Mol Biosci. 2022 Aug 26;9:894247. doi: 10.3389/fmolb.2022.894247. eCollection 2022.
6
Semaphorins as Potential Immune Therapeutic Targets for Cancer.
Front Oncol. 2022 Jan 27;12:793805. doi: 10.3389/fonc.2022.793805. eCollection 2022.
7
The Emerging Roles of π Subunit-Containing GABA Receptors in Different Cancers.
Int J Med Sci. 2021 Oct 31;18(16):3851-3860. doi: 10.7150/ijms.60928. eCollection 2021.
8
TIMELESS Promotes Tumor Progression by Enhancing Macrophages Recruitment in Ovarian Cancer.
Front Oncol. 2021 Aug 19;11:732058. doi: 10.3389/fonc.2021.732058. eCollection 2021.
9
Single-cell characterization of macrophages in glioblastoma reveals MARCO as a mesenchymal pro-tumor marker.
Genome Med. 2021 May 19;13(1):88. doi: 10.1186/s13073-021-00906-x.
10
CTHRC1 promotes liver metastasis by reshaping infiltrated macrophages through physical interactions with TGF-β receptors in colorectal cancer.
Oncogene. 2021 Jun;40(23):3959-3973. doi: 10.1038/s41388-021-01827-0. Epub 2021 May 13.
本文引用的文献
1
Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity.
Cancer Cell. 2013 Dec 9;24(6):695-709. doi: 10.1016/j.ccr.2013.11.007.
2
Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population.
Cancer Res. 2014 Jan 1;74(1):24-30. doi: 10.1158/0008-5472.CAN-13-1196. Epub 2013 Nov 12.
3
Low-dose irradiation programs macrophage differentiation to an iNOS⁺/M1 phenotype that orchestrates effective T cell immunotherapy.
Cancer Cell. 2013 Nov 11;24(5):589-602. doi: 10.1016/j.ccr.2013.09.014. Epub 2013 Oct 24.
4
Macrophage regulation of tumor responses to anticancer therapies.
Cancer Cell. 2013 Mar 18;23(3):277-86. doi: 10.1016/j.ccr.2013.02.013.
5
Neutralizing tumor-promoting chronic inflammation: a magic bullet?
Science. 2013 Jan 18;339(6117):286-91. doi: 10.1126/science.1232227.
6
The good and bad of microglia/macrophages: new hope in stroke therapeutics.
Acta Pharmacol Sin. 2013 Jan;34(1):6-7. doi: 10.1038/aps.2012.178. Epub 2012 Dec 24.
7
Macrophage diversity enhances tumor progression and metastasis.
Cell. 2010 Apr 2;141(1):39-51. doi: 10.1016/j.cell.2010.03.014.
8
The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance.
Immunol Rev. 2008 Apr;222:155-61. doi: 10.1111/j.1600-065X.2008.00607.x.
9
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth.
Cancer Cell. 2007 Jan;11(1):53-67. doi: 10.1016/j.ccr.2006.10.018.
10
The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies.
J Pathol. 2002 Mar;196(3):254-65. doi: 10.1002/path.1027.
Zotero 插件